Comparative Pharmacology
Head-to-head clinical analysis: AMMONUL versus CARBAGLU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONUL versus CARBAGLU.
AMMONUL vs CARBAGLU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonul (sodium phenylacetate and sodium benzoate) provides an alternative pathway for nitrogen excretion. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Benzoate conjugates with glycine to form hippurate, which is also excreted renally. This reduces ammonia levels in patients with urea cycle disorders.
Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.
For acute hyperammonemia: 2.5 g/m² IV over 90 minutes, followed by continuous IV infusion at 2.5 g/m² over 24 hours. For maintenance: 2.5 g/m² IV or oral every 6 hours.
100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.
None Documented
None Documented
Phenylacetate: 0.5-1 hour; phenylacetylglutamine: 1-2 hours. Clinical context: rapid clearance; requires continuous IV infusion for sustained effect.
Terminal half-life approximately 5.8 hours in adults; prolonged in hepatic impairment (up to 10 hours).
Renal: >80% (primarily as phenylacetylglutamine). Biliary/fecal: <5%.
Primarily renal excretion (97% unchanged) with minimal biliary/fecal elimination (<3%).
Category C
Category C
Ammonia Detoxicant
Ammonia Detoxicant